Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Virol. 2012 Oct;86(19):10857-61. doi: 10.1128/JVI.01414-12. Epub 2012 Jul 25.

A combination of broadly neutralizing HIV-1 monoclonal antibodies targeting distinct epitopes effectively neutralizes variants found in early infection.

Author information

  • 1Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.

Abstract

Neutralizing antibody protection against HIV-1 may require broad and potent antibodies targeting multiple epitopes. We tested 7 monoclonal antibodies (MAbs) against 45 viruses of diverse subtypes from early infection. The CD4 binding site MAb NIH45-46W was most broad and potent (91% coverage; geometric mean 50% inhibitory concentration [IC(50)], 0.09 μg/ml). Combining NIH45-46W and a V3-specific MAb, PGT128, neutralized 96% of viruses, while PGT121, another V3-specific MAb, neutralized the remainder. Thus, 2 or 3 antibody specificities may prevent infection by most HIV-1 variants.

PMID:
22837204
[PubMed - indexed for MEDLINE]
PMCID:
PMC3457273
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk